Kiniksa Pharmaceuticals . Class A Stock News

Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.

Companies in The News Are: KNSA,AAPL,VIPS,CCL

Kiniksa (KNSA) reports that the phase III portion of mavrilimumab???s phase II/III study for COVID-related ARDS did not meet the primary efficacy endpoint.

HAMILTON, Bermuda, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a portfolio of assets designed to modulate immunol

Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) is trading lower Tuesday morning after the company announced the Phase 3 trial of mavrilimumab in COVID-19-related ARDS did not meet the primary efficacy en

Wall Street analysts predict that Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) will report sales of $16.32 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Kiniksa Pharmaceuticals earnings. The highest sales estimate is $16.51 million and the lowest is $16.13 million. The firm is scheduled to issue its next earnings report []

Morgan Stanley increased its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 115.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 383,934 shares of the companys stock after acquiring an additional 205,803 shares during the quarter. Morgan Stanley owned about 0.56% []

Kiniksa Pharmaceuticals, Ltd. (KNSA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong

Kiniksa Pharmaceuticals, Ltd. (KNSA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.

Equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) will report $16.32 million in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Kiniksa Pharmaceuticals earnings, with the lowest sales estimate coming in at $16.13 million and the highest estimate coming in at $16.51 million. The firm is []

HAMILTON, Bermuda, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 4th Annual

HAMILTON, Bermuda, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 4th Annual He

Equities analysts expect Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) to report earnings of ($0.45) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Kiniksa Pharmaceuticals earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.41). Kiniksa Pharmaceuticals posted earnings per share of ($0.79) during the same quarter []

The consensus price target hints at a 137.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward tren

The consensus price target hints at a 137.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward tren